Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective.

Abstract:

PURPOSE:To evaluate the association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer (BC) risk. METHODS:A cohort of all Maccabi Healthcare Services (MHS) female members aged 40-50 years between 1/2003 and 12/2013 was used to identify LNG-IUS users as "cases," and 2 age-matched non-users as "controls." Exclusion criteria included: prior BC diagnosis, prior (5 years pre-study) and subsequent treatment with other female hormones or prophylactic tamoxifen. Invasive tumors were characterized by treatments received (chemotherapy, hormonal therapy, trastuzumab, or combination thereof). RESULTS:The analysis included 13,354 LNG-IUS users and 27,324 controls (mean age: 44.1 ± 2.6 vs. 44.9 ± 2.8 years; p < 0.0001). No significant differences in 5-year Kaplan-Meier (KM) estimates for overall BC risk or ductal carcinoma in situ occurrence were observed between groups. There was a trend towards higher risk for invasive BC in LNG-IUS users (5-year KM-estimate: 1.06% vs. 0.93%; p = 0.051). This difference stemmed primarily from the younger women (40-45 years; 0.88% vs. 0.69%, p = 0.014), whereas in older women (46-50 years), it was non-significant (1.44% vs. 1.21%; p = 0.26). Characterization of invasive BC by treatment demonstrated that LNG-IUS users had similar proportions of tumors treated with hormonal therapy, less tumors treated with trastuzumab, (7.5% vs. 14.5%) and more tumors treated with chemotherapy alone (25.8% vs. 14.9%; p = 0.041). CONCLUSIONS:In peri-menopausal women, LNG-IUS was not associated with an increased total risk of BC, although in the subgroup of women in their early 40's, it was associated with a slightly increased risk for invasive tumors.

authors

Siegelmann-Danieli N,Katzir I,Landes JV,Segal Y,Bachar R,Rabinovich HR,Bialik M,Azuri J,Porath A,Lomnicky Y

doi

10.1007/s10549-017-4491-2

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

257-262

issue

1

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-017-4491-2

journal_volume

167

pub_type

杂志文章
  • Specific transcriptional response of four blockers of estrogen receptors on estradiol-modulated genes in the mouse mammary gland.

    abstract::Novel agents for the endocrine therapy of breast cancer are needed, especially in order to take advantage of the multiple consecutive responses observed in metastatic progressing breast cancer following previous hormone therapy, thus delaying the use of cytotoxic chemotherapy with its frequent poor tolerance and serio...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2104-7

    authors: Calvo E,Luu-The V,Belleau P,Martel C,Labrie F

    更新日期:2012-07-01 00:00:00

  • Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer.

    abstract:BACKGROUND:This trial studied the disease-free survival after high-dose chemotherapy in patients in complete remission of metastatic breast cancer. PATIENTS AND METHODS:Thirty women, mean age 42.2 years (range 33-55) with metastatic breast cancer, received high-dose chemotherapy in a phase II study. Patients were elig...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF01806158

    authors: de Vries EG,Rodenhuis S,Schouten HC,Hupperets PS,Dolsma WV,Lebesque JV,Blijham GH,Bontenbal M,Mulder NH

    更新日期:1996-01-01 00:00:00

  • Intra-operative ultrasound versus wire-guided localization in the surgical management of non-palpable breast cancers: systematic review and meta-analysis.

    abstract:INTRODUCTION:The current standard of treatment for non-palpable breast cancers is wire-guided localization (WGL). WGL has its drawbacks and alternatives such as radio-guided surgery (RGL) and intra-operative ultrasound (IOUS) have been developed. The clinical effectiveness of all forms of RGL has been assessed against ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-013-2639-2

    authors: Ahmed M,Douek M

    更新日期:2013-08-01 00:00:00

  • Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients.

    abstract::The association between promoter methylation status and survival was investigated in a large cohort of women with breast cancer, participants in the Long Island Breast Cancer Study Project. Archived tumor tissues (n = 839) were collected from women diagnosed with a first primary invasive or in situ breast cancer in 19...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1712-y

    authors: Cho YH,Shen J,Gammon MD,Zhang YJ,Wang Q,Gonzalez K,Xu X,Bradshaw PT,Teitelbaum SL,Garbowski G,Hibshoosh H,Neugut AI,Chen J,Santella RM

    更新日期:2012-01-01 00:00:00

  • Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.

    abstract:PURPOSE:To evaluate the effect of adjuvant chemotherapy on improving the prognosis of patients with stage I triple-negative breast cancer (TNBC). METHODS:TNBC patients diagnosed in the SEER 18 database from 2010 to 2015 were included. Kaplan-Meier plots and log-rank tests were used to compare the differences in breast...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05776-2

    authors: Du ZL,Wang Y,Wang DY,Zhang L,Bian ZM,Deng Y,Xu CS,Lin DC,Xie L,Jia Y,Gao JD,Zhang BL

    更新日期:2020-09-01 00:00:00

  • The additional cancer yield of clinical breast examination in screening of women at hereditary increased risk of breast cancer: a systematic review.

    abstract::Women at hereditary increased risk of breast cancer are subjected to frequent clinical breast examination (CBE) and radiological evaluation of the breasts. This review appraises the additional cancer yield by CBE in screening of women at increased risk of breast cancer who are also subjected to frequent radiological e...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-014-3074-8

    authors: Roeke T,van Bommel AC,Gaillard-Hemmink MP,Hartgrink HH,Mesker WE,Tollenaar RA

    更新日期:2014-08-01 00:00:00

  • Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.

    abstract::Molecular profiles of asynchronous breast cancer metastases are of clinical relevance to individual patients' treatment, whereas the role of profiles in synchronous lymph node metastases is not defined. The present study aimed to assess individual biomarkers and molecular subtypes according to the St Gallen classifica...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2617-8

    authors: Falck AK,Bendahl PO,Chebil G,Olsson H,Fernö M,Rydén L

    更新日期:2013-07-01 00:00:00

  • Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands.

    abstract::To compare overall survival between women with unilateral breast cancer (UBC) and contralateral breast cancer (CBC). Women with UBC (N = 182,562; 95 %) and CBC (N = 8,912; 5 %) recorded in the Netherlands Cancer Registry between 1989 and 2008 were included and followed until 2010. We incorporated CBC as a time-depende...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2588-9

    authors: Font-Gonzalez A,Liu L,Voogd AC,Schmidt MK,Roukema JA,Coebergh JW,de Vries E,Soerjomataram I

    更新日期:2013-06-01 00:00:00

  • Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk.

    abstract::Integrins are cell surface receptors, which mediate cell-to-cell and cell-to-extracellular matrix adhesion. Some of them, e.g. alpha(V)beta(3), alpha(IIb)beta(3) and alpha(2)beta(1), have been suggested as key players for cancer development and tumor metastasis. Two polymorphisms in the gene for the alpha(2) component...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-9089-4

    authors: Langsenlehner U,Renner W,Yazdani-Biuki B,Eder T,Wascher TC,Paulweber B,Clar H,Hofmann G,Samonigg H,Krippl P

    更新日期:2006-05-01 00:00:00

  • Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer.

    abstract::We have compared by RNA in situ hybridisation on serial cryo-sections the distribution of cathepsin D (cathD), stromelysin 3 (strom-3), and urokinase plasminogen activator (UPA) gene expression in different tissues of human benign and malignant mammary tumors. Cath-D expression was found to be higher in adenocarcinoma...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806676

    authors: Escot C,Zhao Y,Puech C,Rochefort H

    更新日期:1996-01-01 00:00:00

  • Old masters as clinical photographers: multifocal breast cancer diagnosed 400 years ago.

    abstract::It is common belief among physicians the idea that breast cancer was not diagnosed centuries ago. Nevertheless, there are reports suggesting that old masters and even common people knew this dramatic disease. In the 16th and 17th centuries, famous artists painted things exactly as they saw them. This allows the detect...

    journal_title:Breast cancer research and treatment

    pub_type: 历史文章,杂志文章

    doi:10.1007/s10549-007-9753-y

    authors: Grau JJ,Estrach T

    更新日期:2008-09-01 00:00:00

  • Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.

    abstract::The ErbB2 receptor is a proto-oncogene associated with a poor prognosis in breast cancer. Herceptin, the only humanized anti-ErbB2 antibody currently in clinical use, has proven to be an essential tool in the immunotherapy of breast carcinoma, but induces cardiotoxicity. ErbB2 is involved in the growth and survival pa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2103-8

    authors: Fedele C,Riccio G,Malara AE,D'Alessio G,De Lorenzo C

    更新日期:2012-07-01 00:00:00

  • Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.

    abstract::The concept of cancer cells being hierarchically organized and arising from their own progenitor stem cells will have important implications on cancer therapy. If this hypothesis were to be true then the paucity of estrogen receptors in stem cells as well as their inherent drug resistance mechanisms pose a challenge t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0619-3

    authors: Resetkova E,Reis-Filho JS,Jain RK,Mehta R,Thorat MA,Nakshatri H,Badve S

    更新日期:2010-08-01 00:00:00

  • Sexual health in long-term breast cancer survivors.

    abstract:PURPOSE:Sexual dysfunction is reported in women with breast cancer (BC). It is unclear whether symptoms persist over time as data comparing long-term survivors to controls are lacking. We compared sexual functioning in long-term breast cancer survivors (BCS) to controls and determined the impact of adjuvant therapy on ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4894-8

    authors: Soldera SV,Ennis M,Lohmann AE,Goodwin PJ

    更新日期:2018-11-01 00:00:00

  • A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease.

    abstract::Experimental evidence provides strong support for anti-carcinogenic effects of calcium and vitamin D with respect to breast cancer. Observational epidemiologic data also provide some support for inverse associations with risk. We tested the effect of calcium plus vitamin D supplementation on risk of benign proliferati...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-008-0213-0

    authors: Rohan TE,Negassa A,Chlebowski RT,Ceria-Ulep CD,Cochrane BB,Lane DS,Ginsberg M,Wassertheil-Smoller S,Page DL

    更新日期:2009-07-01 00:00:00

  • Analysis of cathepsin D in human breast cancer: usefulness of the processed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients.

    abstract::The relative amounts of the precursor (52 kDa) and processed (31,27 kDa) forms of cathepsin D have been analyzed by Western blotting in biopsied breast tissue cytosols from 134 lesions from invasive breast cancer patients, 24 lesions from patients with ductal carcinoma in situ (DCIS), 227 lesions from benign breast di...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006394401199

    authors: Riley LB,Lange MK,Browne RJ,Cochrane PJ,Choi IJ,Davis B,Arcona S,Alhadeff JA

    更新日期:2000-03-01 00:00:00

  • Digital compared to screen-film mammography: breast cancer prognostic features in an organized screening program.

    abstract::Our previous study found cancer detection rates were equivalent for direct radiography compared to screen-film mammography, while rates for computed radiography were significantly lower. This study compares prognostic features of invasive breast cancers by type of mammography. Approved by the University of Toronto Res...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3088-2

    authors: Prummel MV,Done SJ,Muradali D,Majpruz V,Brown P,Jiang H,Shumak RS,Yaffe MJ,Holloway CM,Chiarelli AM

    更新日期:2014-09-01 00:00:00

  • Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients.

    abstract::Relaxin (RLX) is known to induce remodeling of benign stromal tissues through upregulation of matrix metalloproteases (MMPs). Recently, we could show that RLX also induces MMPs in breast cancer cells and enhances in vitro invasiveness. To investigate its potential role for progression of breast cancer in vivo, RLX ser...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000041622.30169.16

    authors: Binder C,Simon A,Binder L,Hagemann T,Schulz M,Emons G,Trümper L,Einspanier A

    更新日期:2004-09-01 00:00:00

  • Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.

    abstract::The aim of this study was to evaluate the difference in outcomes based on p53 overexpression of patients with breast cancer who received adjuvant therapy following local treatment for invasive ductal carcinoma, not otherwise specified. We analyzed data from 4,683 patients with cancer enrolled in two institutions betwe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-009-0560-5

    authors: Kim HS,Yom CK,Kim HJ,Lee JW,Sohn JH,Kim JH,Park YL,Ahn SH

    更新日期:2010-06-01 00:00:00

  • EpCAM expression is an indicator of recurrence in basal-like breast cancer.

    abstract::Advances in the understanding of the molecular basis of breast cancer have necessitated a definition of more sensitive and specific indicators of prognosis that are central to the underlying cancer biology and that reflect the complicated and heterogeneous nature of the disease. This study investigates the expression ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1813-7

    authors: Agboola AJ,Paish EC,Rakha EA,Powe DG,Macmillan RD,Ellis IO,Green AR

    更新日期:2012-06-01 00:00:00

  • New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth.

    abstract:PURPOSE:Combining molecular therapies with chemotherapy may offer an improved clinical outcome for chemoresistant tumours. Sphingosine-1-phosphate (S1P) receptor antagonist and sphingosine kinase 1 (SK1) inhibitor FTY720 (FTY) has promising anticancer properties, however, it causes systemic lymphopenia which impairs it...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4380-8

    authors: Alshaker H,Wang Q,Srivats S,Chao Y,Cooper C,Pchejetski D

    更新日期:2017-10-01 00:00:00

  • Transforming growth factorβ1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls.

    abstract::In view of the essential role of transforming growth factorβ1 (TGFB1) on both inhibiting the development of early benign breast tumors as well as promoting tumor invasion, the association of TGFB1 L10P polymorphism and breast cancer risk has been widely reported, but results of previous studies were somewhat contradic...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-010-0843-x

    authors: Ma X,Chen C,Xiong H,Li Y

    更新日期:2010-11-01 00:00:00

  • Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer.

    abstract:AIMS:Anthracyclines-taxanes containing regimens are widely used for breast cancer treatment both in neoadjuvant-adjuvant setting and in metastatic disease. Recently high-dose chemotherapy (HDC) with autologous stem cell support has been introduced as adjuvant treatment for high-risk primary breast cancer and for select...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1006462023110

    authors: Zambelli A,Robustelli della Cuna FS,Ponchio L,Ucci G,Da Prada GA,Robustelli della Cuna G

    更新日期:2000-06-01 00:00:00

  • Genetic variants in trinucleotide repeat-containing 9 (TNRC9) are associated with risk of estrogen receptor positive breast cancer in a Chinese population.

    abstract::Trinucleotide repeat-containing 9 (TNRC9), a high mobility group chromatin-associated protein, has been implicated in breast cancer metastasis to the bone. Recently, several single nucleotide polymorphisms (SNPs) of TNRC9 were identified as novel breast cancer susceptibility loci by whole genome association studies, e...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-0809-z

    authors: Liang J,Chen P,Hu Z,Shen H,Wang F,Chen L,Li M,Tang J,Wang H,Shen H

    更新日期:2010-11-01 00:00:00

  • PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer.

    abstract::It has recently been proposed that a three-gene model (SCMGENE) that measures ESR1, ERBB2, and AURKA identifies the major breast cancer intrinsic subtypes and provides robust discrimination for clinical use in a manner very similar to a 50-gene subtype predictor (PAM50). However, the clinical relevance of both predict...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2143-0

    authors: Prat A,Parker JS,Fan C,Perou CM

    更新日期:2012-08-01 00:00:00

  • Obesity and subcutaneous fat patterning in relation to survival of postmenopausal breast cancer patients participating in the DOM-project.

    abstract::The effect of obesity and fat distribution on survival of breast cancer patients was studied prospectively in 241 women with a natural menopause who participated in a breast cancer screening project, the DOM-project in Utrecht, The Netherlands. Mean follow-up time was 9.1 years and endpoint of interest was death from ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00665785

    authors: den Tonkelaar I,de Waard F,Seidell JC,Fracheboud J

    更新日期:1995-05-01 00:00:00

  • Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer.

    abstract:BACKGROUND:Gemcitabine (G) and vinorelbine (V) have favorable safety profile and antitumor activity in metastatic breast cancer. To exploit their different mechanism of action and lack of overlapping toxicity, we performed a phase I and II study of G and V in combination. PATIENTS AND METHODS:Fifty-three patients with...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1013034311284

    authors: Mariani G,Tagliabue P,Zucchinelli P,Brambilla C,Demicheli R,Villa E,Marchianò A,Valagussa P,Bonadonna G,Gianni L

    更新日期:2001-12-01 00:00:00

  • Hormones and hormone receptors in the etiology of breast cancer.

    abstract::Many epidemiologic features of breast cancer suggest that endogenous hormones are of importance in the genesis of this disease. Endocrinologic studies based on total levels of various hormones in serum and urine have provided etiologic clues, but have failed to yield a clear understanding of the hormonal aberrations t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:

    authors: Thomas DB

    更新日期:1986-01-01 00:00:00

  • Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry.

    abstract:RATIONALE:Survival after loco-regional failure (LRF) of breast cancer was investigated at the population level. METHODS:Using the Stockholm cancer registry, 2698 patients diagnosed with LRF between 1980 and 2014 were identified and divided into three cohorts by year of LRF diagnosis. Post-relapse event-free survival (...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4936-2

    authors: Falato C,Taylor SK,Szulkin R,Nordblom A,Eriksson L,Sofiadis A,Fredriksson I,Hartman J,Bergh J,Foukakis T

    更新日期:2018-12-01 00:00:00

  • Breast cancer risk factors and second primary malignancies among women with breast cancer.

    abstract:PURPOSE:To examine the association between breast cancer risk factors and second primary cancers (independent diagnoses occurring at least 12 months after the initial breast cancer diagnosis) among breast cancer survivors. METHODS:In this population-based study, cancer outcomes among breast cancer survivors first diag...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9446-y

    authors: Trentham-Dietz A,Newcomb PA,Nichols HB,Hampton JM

    更新日期:2007-10-01 00:00:00